Amgen Beats Q4 Expectations Despite FDA Drug Controversy
Amgen (AMGN) reports strong Q4 2025 earnings with $9.87B revenue, beating estimates. Company defies FDA request to withdraw Tavneos while advancing obesity drug MariTide through trials.
/ 107 items
#NVO↓
Eli Lilly Crushes Forecasts on Weight-Loss Drug Boom
Eli Lilly (LLY) beats Q4 expectations and projects strong 2026 growth driven by surging demand for Zepbound and Mounjaro, outpacing rival Novo Nordisk.
Novo Nordisk Expects Sales Drop in 2026 Amid Rising Competition
Novo Nordisk forecasts 5-13% sales decline for 2026 as Ozempic and Wegovy face intense competition from Eli Lilly and generics, plus US drug pricing pressures.
Novo Nordisk's Wegovy Weight-Loss Pill Shows Promising Early Sales Data
Novo Nordisk's new Wegovy weight-loss pill records over 3,000 prescriptions in its first four days, signaling strong market entry as competition with Eli Lilly intensifies in the booming obesity treatment sector.
Texas Pharmacy Sues Eli Lilly and Novo Nordisk Over GLP-1 Weight-Loss Drug Access
Strive Specialties files lawsuit against Eli Lilly and Novo Nordisk, alleging drugmakers blocked access to cheaper compounded versions of popular weight-loss medications through exclusive telehealth deals.
Novo Nordisk Hunts for Deals After Losing Metsera to Pfizer
Novo Nordisk CEO says company is open to acquisitions of any size to strengthen its obesity drug portfolio following competition from Eli Lilly and loss of Metsera to Pfizer.